Recombinant Human TGF beta 3 protein(N-His)(active)
Sizes: 20μg, 100μg
Catalogue Numbers: PKSH034198-20, PKSH034198-100
Citations, Manuals and MSDS Available upon request.
Abbreviation: TGF beta 3
Target Symptom: ARVD; ARVD1; LDS5; RNHF; TGFB3; TGF-B3
Target Species: Human
Expression Host: E.coli
Application: Cell culture
Fusion Tag: N-His
UNIProt ID: P10600
Accession: P10600
Background: TGF-beta 3 (transforming growth factor-beta 3) is a member of a TGF-beta superfamily subgroup that is defined by their structural and functional similarities. TGF-beta 3 and its closely related proteins, TGF-beta 1 and ? beta 2, act as cellular switches to regulate immune function, cell proliferation, and epithelial-mesenchymal transition. The non-redundant biological effects of TGF-? beta 3 include involvement in palatogenesis, chondrogenesis, and pulmonary development. Rat TGF-beta 3 cDNA encodes a 412 amino acid (aa) precursor that contains a 23 aa signal peptide and a 389 aa proprotein. TGF-beta 3 is secreted as a latent complex. This latent form of TGF-beta 3 is activated by integrins, thrombospondin-1, plasmin, and matrix metalloproteases. It can also be activated by extreme pH and reactive oxygen species. TGF-beta 3 binds with high affinity to TGF-beta RII, a type II serine/threonine kinase receptor. This receptor then phosphorylates and activates type I serine/threonine kinase receptors, TGF-? beta RI or ALK-?1, to modulate transcription through Smad phosphorylation. The divergent biological effects exerted by individual TGF-beta isoforms is dependent upon the recruitment of co-receptors (TGF-beta RIII and endoglin) and the subsequent initiation of Smad--dependent or -independent signaling pathways.
Activity: Measure by its ability to inhibit IL-4-induce proliferation in HT-2 cells. The ED50 for this effect is < 50 pg/mL. The specific activity of recombinant human TGF beta 3 is > 2 x 107IU/mg.
Sequence: MKMHLQRALVVLALLNFATVSLSLSTCTTLDFGHIKKKRVEAIRGQILSKLRLTSPPEPTVMTHVPYQVLALYNSTRELLEEMHGEREEGCTQENTESEYYAKEIHKFDMIQGLAEHNELAVCPKGITSKVFRFNVSSVEKNRTNLFRAEFRVLRVPNPSSKRNEQRIELFQILRPDEHIAKQRYIGGKNLPTRGTAEWLSFDVTDTVREWLLRRESNLGLEISIHCPCHTFQPNGDILENIHEVMEIKFKGVDNEDDHGRGDLGRLKKQKDHHNPHLILMMIPPHRLDNPGQGGQRKKRALDTNYCFRNLEENCCVRPLYIDFRQDLGWKWVHEPKGYYANFCSGPCPYLRSADTTHSTVLGLYNTLNPEASASPCCVPQDLEPLTILYYVGRTPKVEQLSNMVVKSCKCS
Purity: > 98 % as determined by reducing SDS-PAGE.
Formulation: Lyophilized from a solution containing 20 mM sodium citrate, 0.2 M NaCl, pH 3.5.
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the printed manual.
Reconstitution: Please refer to the printed manual for detailed information.
Endotoxin: < 0.1 EU per μg of the protein as determined by the LAL method.
Calculated MW: 48.16 kDa
Storage: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.
Shipping: This product is provided as lyophilized powder which is shipped with ice packs.
Research Use Only